Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lynparza's Wider Prospects Boosted By Late-Stage Breast Cancer Study

Executive Summary

Hopes for wider use of AstraZeneca Lynparza (olaparib) were boosted by Phase III data showing improved survival rates in patients with a certain type of breast cancer who used the PARP inhibitor compared with chemotherapy alone.

Advertisement

Related Content

A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck
AstraZeneca's OlympiAD Trial Kick-Starts PARP In Breast Cancer
It's Not All About IO: Seven Drugs To Watch At ASCO
Few Q1 Bright Spots For AstraZeneca Puts Pressure On The Pipeline
1Q Pharma Results Preview: Biogen, Novartis, Lilly, Amgen, GSK, AstraZeneca, BMS, AbbVie, Roche, Bayer, Sanofi
AstraZeneca Updates MYSTIC Plan In Bid To Challenge Merck In NSCLC
AbbVie Makes Further Inroads In Oncology As Humira Loss Looms
Lynparza May Still Rival Tesaro's Niraparib In Ovarian Cancer Therapy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098254

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel